Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance

A Novel PCR Assay for Quantification of HIV-1 RNA

(2013) L. Shan et al.   JOURNAL OF VIROLOGY

No Evidence for Evolution of Protease Inhibitor Resistance from Standard Genotyping, After Three Years of Treatment with Darunavir/Ritonavir, With or Without Nucleoside Analogues

(2012) Federico Pulido et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Antiretroviral dynamics determines HIV evolution and predicts therapy outcome

(2012) Daniel I S Rosenbloom et al.   NATURE MEDICINE

A quantitative basis for antiretroviral therapy for HIV-1 infection

(2012) Benjamin L Jilek et al.   NATURE MEDICINE

Maturation-Dependent HIV-1 Surface Protein Redistribution Revealed by Fluorescence Nanoscopy

(2012) J. Chojnacki et al.   SCIENCE

Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)

(2011) Babafemi Taiwo et al.   AIDS

Interplay between Single Resistance-Associated Mutations in the HIV-1 Protease and Viral Infectivity, Protease Activity, and Inhibitor Sensitivity

(2011) Gavin J. Henderson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Influence of Host Gene Transcription Level and Orientation on HIV-1 Latency in a Primary-Cell Model

(2011) L. Shan et al.   JOURNAL OF VIROLOGY

New Insights into HIV Assembly and Trafficking

(2011) Muthukumar Balasubramaniam et al.   PHYSIOLOGY

Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance

(2011) M. E. S. Sampah et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Critical Subset Model Provides a Conceptual Basis for the High Antiviral Activity of Major HIV Drugs

(2011) L. Shen et al.   Science Translational Medicine

Full-length HIV-1 Gag determines protease inhibitor susceptibility within in-vitro assays

(2010) Ravindra K Gupta et al.   AIDS

Three Residues in HIV-1 Matrix Contribute to Protease Inhibitor Susceptibility and Replication Capacity

(2010) Chris M. Parry et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Protease inhibitor monotherapy

(2010) Ignacio Pérez-Valero et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Antiretroviral Treatment of Adult HIV Infection

(2010) Melanie A. Thompson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

In Vitro Selection of Highly Darunavir-Resistant and Replication-Competent HIV-1 Variants by Using a Mixture of Clinical HIV-1 Isolates Resistant to Multiple Conventional Protease Inhibitors

(2010) Y. Koh et al.   JOURNAL OF VIROLOGY

Molecular Basis for Drug Resistance in HIV-1 Protease

(2010) Akbar Ali et al.   Viruses-Basel

HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review

(2009) Wouter FW Bierman et al.   AIDS

HIV-1 Gag Processing Intermediates Trans-dominantly Interfere with HIV-1 Infectivity

(2009) Barbara Müller et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Human Immunodeficiency Virus Type 1 Protease-Correlated Cleavage Site Mutations Enhance Inhibitor Resistance

(2009) M. Kolli et al.   JOURNAL OF VIROLOGY

Gag Mutations Strongly Contribute to HIV-1 Resistance to Protease Inhibitors in Highly Drug-Experienced Patients besides Compensating for Fitness Loss

(2009) Elisabeth Dam et al.   PLoS Pathogens

Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection

(2008) Lin Shen et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs

(2008) Lin Shen et al.   NATURE MEDICINE